Document Detail


Summary of clinical trials with zafirlukast.
MedLine Citation:
PMID:  9647606     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Zafirlukast is an orally active and selective cysteinyl leukotriene (cysLT) receptor antagonist. In humans, zafirlukast antagonized the effects of exogenously administered LTD4 and cysLTs released endogenously in response to physical and chemical stimuli. Zafirlukast antagonized LTD4-induced bronchoconstriction, with effects still evident 12 h after drug administration. In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma. In multicenter trials in patients with chronic, stable asthma, zafirlukast reduced asthma symptoms, decreased as-needed beta-agonist use, and improved pulmonary function without increasing the number of adverse events. Zafirlukast also exhibited evidence of an anti-inflammatory effect in the lung in preliminary studies involving segmental antigen challenge. The results from these clinical trials demonstrate that zafirlukast is effective and safe for the prophylactic treatment of asthma.
Authors:
W J Calhoun
Related Documents :
16455346 - 6. asthma: factors underlying inception, exacerbation, and disease progression.
2058816 - Bricanyl turbuhaler and ventolin rotahaler in exercise-induced asthma in children.
1330676 - Dose duration of nebulized nedocromil sodium in exercise-induced asthma.
1308496 - A comparative study of bronchodilator actions of ipratropium bromide (atrovent) & salbu...
10700686 - Longitudinal evaluation of cardiopulmonary performance during exercise after bone marro...
1176386 - Turnover of free fatty acids during recovery from exercise.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of respiratory and critical care medicine     Volume:  157     ISSN:  1073-449X     ISO Abbreviation:  Am. J. Respir. Crit. Care Med.     Publication Date:  1998 Jun 
Date Detail:
Created Date:  1998-07-09     Completed Date:  1998-07-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9421642     Medline TA:  Am J Respir Crit Care Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S238-45; discussion S245-8     Citation Subset:  AIM; IM    
Affiliation:
Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pennsylvania 15261, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Asthmatic Agents / pharmacology,  therapeutic use*
Anti-Inflammatory Agents, Non-Steroidal / pharmacology
Asthma / drug therapy*,  etiology,  metabolism,  physiopathology
Bronchoconstriction / drug effects*
Clinical Trials as Topic
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Drug Interactions
Humans
Leukotriene Antagonists*
Multicenter Studies as Topic
Tosyl Compounds / pharmacology,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Asthmatic Agents; 0/Anti-Inflammatory Agents, Non-Steroidal; 0/Leukotriene Antagonists; 0/Tosyl Compounds; 107753-78-6/zafirlukast

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors.
Next Document:  Basic and clinical aspects of myocardial stunning.